# Pathopharm-II-Antibiotics
#separator:tab
#html:true
"<span style=""color:red; font-weight:bold; text-allign:center""><span style=""color: rgb(255, 0, 0);""><b>Azithromycin</b></span></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0); text-align: center;"">Macrolide</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">Mild to moderate infections of the upper respiratory tract, in children: acute otitis media, lower respiratory tract; uncomplicated skin and skin structure infections, nongonococcal urethritis, or cervicitis</span><span style=""text-align: center;"">,</span><span style=""text-align: center;"">&nbsp;prophylaxis</span><span style=""text-align: center;"">,&nbsp;</span><span style=""text-align: center;"">bacterial conjunctivitis</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Binds to 50S ribosomal subunits of susceptible bacteria and suppresses protein synthesis; much greater spectrum of activity than erythromycin; more effective against gram-negative organisms</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Dizziness, headache, vertigo, somnolence, fatigue, palpitations, chest pain, nausea, diarrhea, abdominal pain, stomatitis, heartburn, dyspepsia, flatulence, melena, vaginitis, nephritis, anemia, rash, photosensitivity, pain at injection site</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Seizures,&nbsp;QT prolongation, torsades de pointes (rare),&nbsp;hepatotoxicity,&nbsp;cholestatic jaundice, CDAD,&nbsp;leukopenia, thrombocytopenia, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <i>Most infections</i><br><ul><li>Adult: PO 500 mg on day 1, then 250 mg daily on days 2-5 for a total dose of 1.5 g or 500 mg a day × 3 days</li></ul><i>Pelvic inflammatory disease</i><br><ul><li>Adult: PO/IV 500 mg IV q24hr × 2 doses, then 250 mg PO q24hr × 7-10 days</li></ul><i>Cervicitis, chlamydia, chancroid, nongonococcal urethritis, syphilis</i><br><ul><li>Adult: PO 1 g single dose</li></ul><i>Gonorrhea</i><br><ul><li>Adult: PO 1 g single dose with ceftriaxone 250 mg IM</li></ul><i>Endocarditis prophylaxis</i><br><ul><li>Adult: PO 500 mg 1 hr prior to procedure</li></ul><i>Community acquired pneumonia</i><br><ul><li>Adult: PO/IV 500 mg q 24 hr (IV, severe) × 2 doses, then 500 mg q 24 hr × 7-10 days; 500 mg (PO), then 250 mg/day × 4 more days or 2 g single dose (Zmax)</li></ul><i>Mac in HIV</i><br><ul><li>Adult: PO 500-600 mg q day</li></ul><i>Lower respiratory tract infections</i><br><ul><li>Adult: PO 500 mg day 1, then 250 mg × 4 days</li></ul><i>Bacterial conjunctivitis</i><br><ul><li>Adult/child ≥ 1 yr: opthalmic instill 1 drop in affected eye bid × 2 days then 1 drop in eye q day × 5 days</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul style=""color: rgb(0, 255, 0);""><li>QT prolongation, torsades de pointes: Assess for patients with serious bradycardia, ongoing pro-arrhythmic conditions, or elderly; more common in these patients</li><li>Assess for signs and symptoms of infection: drainage, fever, increased WBC &gt;10,000/mm3, urine culture positive, sore throat, sputum culture positive</li><li>Monitor respiratory status: rate, character, wheezing, tightness in chest; discontinue product if these occur</li><li>Monitor allergies before treatment, reaction of each medication; place allergies on chart, notify all people giving products; skin eruptions, itching</li><li>Monitor I&amp;O ratio, renal studies; report hematuria, oliguria in renal disease; check urinalysis, protein, blood</li><li>Monitor liver studies: AST, ALT, bilirubin, LDH, alkaline phosphatase; CBC with diff</li><li>Monitor C&amp;S before product therapy; product may be taken as soon as culture is taken; C&amp;S may be repeated after treatment</li><li>Assess for serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, discontinue if rash occurs</li><li>Assess for CDAD: blood or pus in diarrhea stool, abdominal pain, fever, fatigue, anorexia; obtain CBC, serum albumin</li><li>Assess for superinfection: sore throat, mouth, tongue; fever, fatigue, diarrhea, anogenital pruritus</li><li>Pregnancy/breastfeeding: Use only if clearly needed, cautious use in breastfeeding, excreted in breast milk</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><span style=""color: rgb(255, 0, 0);""><b>Bactrim (sulfamethoxazole/trimethoprim, Septra)</b></span></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0); text-align: center;"">Sulfonamide</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">UTI, otitis media, acute and chronic prostatitis, shigellosis, chancroid, traveler’s diarrhea</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> <div style=""text-align: left;""><span style=""color: rgb(0, 255, 0);"">Sulfamethoxazole (SMZ) interferes with bacterial biosynthesis of proteins by competitive antagonism of PABA when adequate levels are maintained; trimethoprim (TMP) blocks synthesis of tetrahydrofolic acid; combination blocks two consecutive steps in bacterial synthesis of essential nucleic acids, protein</span><br></div></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Headache, insomnia, hallucinations, depression, vertigo, fatigue, anxiety, seizures, drug fever, chills, tinnitus, nausea, vomiting, abdominal pain, stomatitis, glossitis, pancreatitis, diarrhea, anorexia,&nbsp;increased BUN, creatinine; crystalluria, rash, dermatitis, urticaria, erythema, photosensitivity, pain, inflammation at injection site, cough, SOB</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Aseptic meningitis, allergic myocarditis, hepatitis, enterocolitis, , pseudomembranous colitis, renal failure, toxic nephrosis, leukopenia, neutropenia, thrombocytopenia, agranulocytosis, hemolytic anemia, hypoprothrombinemia, Henoch-Schönlein purpura, methemoglobinemia, eosinophilia, anaphylaxis, systemic lupus erythematosus, Stevens-Johnson syndrome</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <i>Most infections</i><br><ul><li>Adult/child &gt;2 mo: PO/IV 6-12 mg TMP/kg/day divided q12hr</li></ul><i>UTI</i><br><ul><li>Adult: PO 160 mg TMP q12hr × 10-14 days</li></ul><i>Chronic bronchitis</i><br><ul><li>Adult: PO 160 mg TMP q12hr × 10-14 days</li></ul><i>Serious infections/Pneumocystis jirovecii pneumonitis</i><br><ul><li>Adult and child: PO 15-20 mg/kg TMP daily in 4 divided doses q6hr × 14-21 days; IV 15-20 mg/kg/day (based on TMP) in 3-4 divided doses for up to 14 days</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul style=""color: rgb(0, 255, 0);""><li>Monitor I&amp;O ratio; note color, character, pH of urine if product administered for UTI; output should be 800 mL less than intake; if urine is highly acidic, alkalization may be needed</li><li>Monitor renal function tests: BUN, creatinine, urinalysis (long-term therapy)</li><li>Assess type of infection; obtain C&amp;S before starting therapy</li><li>Assess blood dyscrasias, skin rash, fever, sore throat, bruising, bleeding, fatigue, joint pain</li><li>Assess allergic reaction: Rash, dermatitis, urticaria, pruritus, dyspnea, bronchospasm, AIDS patients are more susceptible, identify if patient has a sulfa allergy</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><b><span style=""color: rgb(255, 0, 0);"">Cefazolin</span></b></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0); text-align: center;"">Cephalosporin</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">Upper, lower respiratory tract, urinary tract, skin infections; otitis media; tonsillitis, UTI</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Inhibits bacterial cell wall synthesis, rendering cell wall osmotically unstable, leading to cell death</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Headache, dizziness, nausea, vomitting, diarrhea, anorexia, abdominal pain, rash, urticaria, dermatitis, injection site reactions</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Seizures,&nbsp;Clostridium difficile-associated diarrhea (CDAD), leukopenia, thrombocytopenia, agranulocytosis, neutropenia, hemolytic anemia, anaphylaxis, serum sickness, superinfection, Stevens-Johnson syndrome, toxic epidermal necrolysis</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <u>cefadroxil</u><br><i>UTI</i><br><ul><li>Adult: PO 1-2 g daily or divided q12hr, give a loading dose of 1 g initially</li></ul><u>ceFAZolin</u><br><i>Life-threatening infections</i><br><ul><li>Adult: IM/IV 1-2 g q6-8hr, max 12 g/day</li></ul><i>Mild/moderate infections</i><br><ul><li>Adult: IM/IV 250 mg-1 g q8hr, max 12 g/day</li></ul><i>Surgical prophylaxis</i><br><ul><li>Adult &lt;120 kg: IM/IV 1-2 g ≥120 kg 3 g</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul style=""color: rgb(0, 255, 0);""><li>Assess patient for signs and symptoms of infection including characteristics of wounds, sputum, urine, stool, WBC &gt;10,000/mm3, earache, fever; obtain baseline information and during treatment</li><li>Assess patient for previous sensitivity reaction to penicillins or other cephalosporins; cross-sensitivity between penicillins and cephalosporins is common</li><li>Obtain C&amp;S before beginning product therapy to identify if correct treatment has been initiated, may start treatment before receiving results</li><li>Assess for anaphylaxis: rash, urticaria, pruritus, chills, fever, joint pain; angioedema may occur a few days after therapy begins; EPINEPHrine and resuscitation equipment should be available for anaphylactic reaction</li><li>Monitor blood studies: AST, ALT, CBC, Hct, bilirubin, LDH, alkaline phosphatase, Coombs’ test if patient is on long-term therapy</li><li>Assess for Stevens-Johnson syndrome, toxic epidermal necrolysis: monitor for painful rash, flu-like symptoms, discontinue product and do not restart</li><li>CDAD: Assess bowel pattern daily, if severe diarrhea occurs, product should be discontinued, may indicate CDAD</li><li>Assess for superinfection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><b><span style=""color: rgb(255, 0, 0);"">Ceftriaxone</span></b></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0); text-align: center;"">3rd Gen Cephalosporin</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">Uncomplicated skin and skin structure infections, community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis, tonsillitis, otitis media</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> <div style=""text-align: left;""><span style=""color: rgb(0, 255, 0);"">Inhibits bacterial cell wall synthesis, rendering cell wall osmotically unstable, leading to cell death</span></div></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Headache, dizziness, nausea, vomiting, diarrhea, anorexia, abdominal pain, cholestasis (cefotaxime), pruritus, candidiasis, increased BUN, rash, urticaria, dermatitis, injection site reaction, arthralgia (cefditoren)</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Seizures, clostridium difficile-associated diarrhea (CDAD), nephrotoxicity, renal failure, leukopenia, thrombocytopenia, agranulocytosis, neutropenia, lymphocytosis, eosinophilia, hemolytic anemia, anaphylaxis, serum sickness, Stevens-Johnson syndrome, toxic epidermal necrolysis</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <u>cefdinir</u><br><i>Uncomplicated skin and skin structure infections/community-acquired pneumonia</i><br><ul><li>Adult and child ≥13 yr: PO 300 mg q12hr × 10 days or 600 mg q 24 hr; max 600 mg/day</li></ul><i>Acute exacerbations of chronic bronchitis/acute maxillary sinusitis</i><br><ul><li>Adult and child ≥13 yr: PO 300 mg q12hr or 600 mg q24hr × 10 days; max 600 mg/day</li></ul><i>Pharyngitis/tonsillitis</i><br><ul><li>Adult and child ≥13 yr: PO 300 mg q12hr or 600 mg q24hr × 5-10 days; max 600 mg/day</li></ul><i>Renal dose</i><br><ul><li>Adult/child ≥13 yr: PO CCr &lt;30 mL/min 300 mg q24hr</li></ul>cefditoren pivoxil<br><ul><li>Adult: PO 200-400 mg bid × 10-14 days</li></ul><u>cefepime</u><br><i>Febrile neutropenia</i><br><ul><li>Adult/adolescent &gt;16 yr/child ≥40 kg: IV 2 g q8hr × 7 days or until neutropenia resolves</li></ul><i>Urinary tract infections (mild to moderate)</i><br><ul><li>Adult/adolescent &gt;16 yr: IV/IM 0.5-1 g q12hr × 7-10 days</li></ul><i>Urinary tract infections (severe)</i><br><ul><li>Adult/adolescent &gt;16 yr: IV 2 g q12hr × 10 days</li></ul><i>Pneumonia (moderate to severe)</i><br><ul><li>Adult: IV 1-2 g q8–12hr × 10 days</li></ul><i>Moderate-severe skin/structure infections due to Staphylococcus aureus or Streptococcus pyogenes; or for diabetic foot ulcer (unlabeled)</i><br><ul><li>Adult: IV: 2 g q12h for 10 days</li></ul><i>Complicated intra-abdominal infections (peritonitis), biliary tract infections (cholangitis, cholecystitis)</i><br><ul><li>Adult/adolescent 17 yr: IV: 2 g q12h with metronidazole for 7-10 days; for infections caused by Pseudomonas aeruginosa, 2 g q8h</li></ul><u>cefixime</u><br><ul><li>Adult/adolescent/child &gt;12 yr or &gt;45 kg: PO 400 mg/day divided q12-24hr</li></ul><u>cefotaxime</u><br><ul><li>Adult/adolescent/child ≥50 kg: IV/IM (uncomplicated infections) 1 g q12hr, (moderate-severe infections) 1-2 g q8hr, (severe infections) 2 g q6-8hr, (life-threatening infections) 2 g q4hr, max 12 g/day</li></ul><u>cefpodoxime</u><br><i>Pneumonia</i><br><ul><li>Adult/child &gt;13 yr: PO 200 mg q12hr for 14 days</li></ul><i>Skin and skin structure</i><br><ul><li>Adult/child &gt;13 yr: PO 400 mg q12hr for 7-14 days</li></ul><i>Pharyngitis and tonsillitis</i><br><ul><li>Adult/child &gt;13 yr: PO 100 mg q12hr for 5-10 days</li></ul><i>Uncomplicated UTI</i><br><ul><li>Adult/child &gt;13 yr: PO 100 mg q12hr for 7 days; dosing interval increased in presence of severe renal impairment</li></ul><u>cefTAZidime</u><br><ul><li>Adult: IV/IM 1-2 g q8-12hr × 5-10 days</li></ul><u>cefTRIAXone</u><br><ul><li>Adult/child &gt;12 yr: IM/IV 1-2 g daily, max 4 g q24hr</li></ul><i>Meningitis</i><br><ul><li>Adult: IV 4 g/day divided q 12 to 24 hours</li></ul><i>Uncomplicated gonorrhea</i><br><ul><li>Adult: 250 mg IM as single dose with azithromycin 1 g single dose or doxycycline 100 mg bid × 7 days</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul style=""color: rgb(0, 255, 0);""><li>Assess patient for previous sensitivity reaction to penicillins or other cephalosporins; cross-sensitivity between penicillins and cephalosporins is common</li><li>Assess patient for signs and symptoms of infection including characteristics of wounds, sputum, urine, stool, WBC &gt;10,000/mm3, fever; obtain baseline information and during treatment</li><li>Obtain C&amp;S before beginning product therapy to identify if correct treatment has been initiated, may start treatment before results are received</li><li>Assess for anaphylaxis: rash, urticaria, pruritus, chills, fever, joint pain; angioedema may occur a few days after therapy begins; EPINEPHrine and resuscitation equipment should be available for anaphylactic reaction</li><li>Monitor blood studies: AST, ALT, CBC, Hct, bilirubin, LDH, alkaline phosphatase, Coombs’ test monthly if patient is on long-term therapy</li><li>Monitor electrolytes: potassium, sodium, chloride monthly if patient is on long-term therapy</li><li>Clostridium difficile-associated diarrhea: Assess bowel pattern daily; if severe diarrhea occurs, product should be discontinued; may indicate CDAD</li><li>Serious skin disorders: Assess for beginning rash, toxic epidermal necrolysis, Stevens Johnson syndrome may occur</li><li>Assess for overgrowth of infection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><b><span style=""color: rgb(255, 0, 0);"">Ciprofloxacin</span></b></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0); text-align: center;"">Fluoroquinolone</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">Adult urinary tract infections (including complicated); chronic bacterial prostatitis; acute sinusitis; infectious diarrhea; typhoid fever; plague, complicated intra-abdominal infections; nosocomial pneumonia; exposure to inhalation anthrax</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Interferes with conversion of intermediate DNA fragments into high-molecular-weight DNA in bacteria; DNA gyrase inhibitor</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Headache, dizziness, fatigue, insomnia, depression, restlessness, confusion, hallucinations, nausea, increased ALT, AST, flatulence, vomiting, diarrhea, abdominal pain, Clostridium difficile-associated diarrhea (CDAD), vaginitis, hypo-hyperglycemia, rash, pruritus, urticaria, photosensitivity, injection site reactions, arthralgia, tendon rupture</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Seizures, suicidal ideation, pseudotumor cerebri, pancreatitis, toxic epidermal&nbsp;</span><span style=""color: rgb(0, 255, 0);"">necrolysis, anaphylaxis, Stevens-Johnson syndrome, QT prolongation, pseudotumor cerebri</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <i>Uncomplicated urinary tract infections</i><br><ul><li>Adult: PO 250 mg q12hr × 3 days or XL 500 mg q24hr × 3 days</li></ul><i>Complicated/severe urinary tract infections</i><br><ul><li>Adult: PO 500 mg q12hr or XL 1000 mg q24hr × 7-14 days; IV 400 mg q12hr</li></ul><i>Respiratory, bone, skin, joint infections (mild-moderate)</i><br><ul><li>Adult: PO 500-750 mg q12hr × 7-14 days; IV 400 mg q12hr</li></ul><i>Nosocomial pneumonia</i><br><ul><li>Adult: IV 400 mg q8hr × 10-14 days</li></ul><i>Intra-abdominal infections, complicated</i><br><ul><li>Adult: PO 500 mg q12hr × 7-14 days, IV 400 mg q12hr × 7-14 days, usually given with metroNIDAZOLE</li></ul><i>Acute sinusitis, mild/moderate</i><br><ul><li>Adult: PO 500 mg q12hr × 10 days; IV 400 mg q12hr × 10 days</li></ul><i>Inhalational anthrax (postexposure)</i><br><ul><li>Adult: PO 500 mg q12hr × 60 days; IV 400 mg q12hr × 60 days</li></ul><i>Plague</i><br><ul><li>Adult IV: 400 mg q8-12hr or PO 500-750 q12hr × 14 days</li></ul><i>Infectious diarrhea</i><br><ul><li>Adult: PO 500-750 mg q12hr × 5-7 days</li></ul><i>Chronic bacterial prostatitis</i><br><ul><li>Adult: PO 500 mg q12hr × 28 days; IV 400 mg q12hr × 28 days</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul style=""color: rgb(0, 255, 0);""><li>Assess patient for previous sensitivity reaction<br></li><li>Assess patient for signs and symptoms of infection including characteristics of wounds, sputum, urine, stool, WBC &gt;10,000/mm3, fever; obtain baseline information before, during treatment</li><li>Assess for Stevens Johnson syndrome, anaphylaxis: rash, urticaria, dyspnea, pruritus, chills, fever, joint pain; discontinue immediately, have emergency equipment nearby may occur a few days after therapy begins; EPINEPHrine and resuscitation equipment should be available for anaphylactic reaction</li><li>Labs: Monitor: AST, ALT, CBC, Hct, bilirubin, LDH, alkaline phosphatase, Coombs’ test monthly if patient is on long-term therapy<br></li><li>QT prolongation: monitor for changes in QTc if taking other products that increase QT</li><li>Assess for CNS symptoms: headache, dizziness, fatigue, insomnia, depression, seizures</li><li>Assess for overgrowth of infection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum<br></li><li>Pseudomotor cerebri: may occur at excessive doses</li><li>Clostridium difficile–associated diarrhea (CDAD); monitor for diarrhea, abdominal pain, cramps, fever, bloody stools, usually occurs several weeks after completion of therapy, report to prescriber immediately</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><b><span style=""color: rgb(255, 0, 0);"">Doxycycline</span></b></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0); text-align: center;"">Tetracycline</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">Syphilis, gonorrhea, lymphogranuloma venereum, uncommon gram-negative or gram-positive organisms, malaria prophylaxis, many different interactions</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Inhibits protein synthesis, phosphorylation in microorganisms by binding to 30S ribosomal subunits, reversibly binding to 30S ribosomal subunits; bacteriostatic</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> <div>Fever, headache, pericarditis, dysphagia, glossitis, decreased calcification of deciduous teeth, oral candidiasis, tooth discoloration, nausea, abdominal pain, vomiting, diarrhea, anorexia, enterocolitis, flatulence, abdominal cramps, gastric burning, stomatitis, increased BUN, rash, urticaria, photosensitivity, increased pigmentation, pruritus, phlebitis, injection site reaction, bone growth retardation (child &lt;8 yr), muscle, joint pain, cough</div></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Hepatotoxicity, CDAD, eosinophilia, neutropenia, thrombocytopenia, hemolytic anemia, exfoliative dermatitis, DRESS,&nbsp;Stevens-Johnson syndrome, angioedema, toxic epidermal necrolysis</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <i>Most infections</i><br><ul><li>Adult: PO/IV 100 mg q12hr on day 1, then 100 mg/day; IV 200 mg in 1-2 INF on day 1, then 100-200 mg/day</li></ul><i>Gonorrhea (patients allergic to penicillin)</i><br><ul><li>Adult: PO 100 mg q12hr × 7 days, or 300 mg followed 1 hr later by another 300 mg</li></ul><i>Malaria prophylaxis</i><br><ul><li>Adult: 100 mg/day 1-2 days before travel, daily during travel, and 4 wk after return</li></ul><i>Chlamydia trachomatis</i><br><ul><li>Adult: PO 100 mg bid × 7 days</li></ul><i>Syphilis (early)</i><br><ul><li>Adult: PO 100 mg bid × 14 days or 120 mg Doryx MPC bid × 14 days</li></ul><i>Primary/secondary syphilis (allergic to penicillin)</i><br><ul><li>Adult: PO 300 mg daily divided × 14 days</li></ul><i>Anthrax (postexposure)</i><br><ul><li>Adult and child &gt;8 yr, ≥45 kg: IV 100 mg q12hr, change to PO when able × 60 days total</li></ul><i>Lyme disease</i><br><ul><li>Adult: PO 100 mg bid × 14-21 days</li></ul><i>Periodontitis</i><br><ul><li>Adult: 20 mg bid after sealing and root planing for ≤9 mo; give close to meal AM or PM</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul style=""color: rgb(0, 255, 0);""><li>Assess patient for previous sensitivity reaction<br></li><li>Assess patient for signs and symptoms of infection including characteristics of wounds, sputum, urine, stool, WBC &gt;10,000/mm3, fever; obtain baseline information before, during treatment</li><li>Obtain C&amp;S before beginning product therapy to identify if correct treatment has been initiated, first dose may be given before results are received</li><li>Assess for allergic reactions: Assess for rash, urticaria, pruritus, chills, fever, joint pain; angioedema may occur a few days after therapy begins, discontinue</li><li>CDAD: Assess bowel pattern daily (diarrhea, abdominal pain, fever, blood in stools); if severe diarrhea occurs, product should be discontinued, may occur several weeks to months after treatment</li><li>Monitor for bleeding: ecchymosis, bleeding gums, hematuria, stool guaiac daily if on long-term therapy; blood dyscrasias may occur</li><li>Assess for overgrowth of infection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</li><li>DRESS: Assess for rash, fever, facial swelling, lymphadenopathy; discontinue</li><li>Labs: Monitor hepatic and renal studies, CBC baseline and periodically</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><b><span style=""color: rgb(255, 0, 0);"">Erythromycin</span></b></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0); text-align: center;"">Macrolide</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">Mild to moderate respiratory tract, skin, soft tissue infections, Legionnaire’s disease, syphilis</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Binds to 50S ribosomal subunits of susceptible bacteria and suppresses protein synthesis</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Nausea, vomiting, diarrhea, abdominal pain, stomatitis, heartburn, anorexia, pruritus ani, vaginitis, moniliasis, rash, urticaria, pruritus, thrombophlebitis, injection-site reactions (IV site)</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Seizur</span><span style=""color: rgb(0, 255, 0);"">es (rare), dysrhythmias, QT prolongation,&nbsp;Clostridium difficile–associated diarrhea (CDAD), esophagitis, hepatotoxicity, anaphylaxis</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <i>Acne</i><br><ul><li>Adult/child &gt;12 yr: TOP applied bid 2%</li></ul><i>Most infections</i><br><ul><li>Adults PO (base, stearate): 250 mg q6hr or 333 mg q8hr or 500 mg q12hr; (ethylsuccinate) 400 mg q6hr or 800 mg q12hr; IV 250-500 mg</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul style=""color: rgb(0, 255, 0);""><li>Assess patient for previous sensitivity reaction</li><li>Assess patient for signs and symptoms of infection including characteristics of wounds, sputum, urine, stool, WBC &gt;10,000/mm3, earache, fever; obtain baseline information before, during treatment</li><li>Obtain C&amp;S test results before beginning product therapy to identify if correct treatment has been initiated, may give first dose before results are received</li><li>Assess for allergic reactions: Rash, urticaria may occur a few days after therapy begins</li><li>Monitor blood studies: AST, ALT, CBC, Hct, bilirubin, LDH, alkaline phosphatase, Coombs’ test monthly if patient is on long-term therapy</li><li>Assess for overgrowth of infection: Perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</li><li>CDAD: Assess for diarrhea with blood, mucus, abdominal pain, fever, product should be discontinued immediately</li><li>Anaphylaxis: Assess for generalized hives, itching, flushing, swelling of lips/tongue/throat, wheezing; have emergency equipment nearby</li><li>QT prolongation: May occur (IV &gt;15 mg/min), those with electrolyte imbalances, congenital QT prolongation, and the elderly are at greater risk; correct electrolyte imbalances prior to treatment; monitor ECG</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><b><span style=""color: rgb(255, 0, 0);"">Nitrofurantoin</span></b></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0); text-align: center;"">Synthetic&nbsp;nitrofuran derivative</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">Urinary tract infections</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Inhibits bacterial acetyl-CoA from interfering with carbohydrate metabolism</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Dizziness, headache, drowsiness, peripheral neuropathy, chills, confusion, vertigo<br style=""color: rgb(0, 255, 0);"">chest pain, nausea, vomiting, abdominal pain, diarrhea, loss of appetite, pancreatitis, pruritus, rash, urticaria, alopecia, tooth staining, arthralgia, myalgia, numbness, peripheral neuropathy, cough, dyspnea, pneumonitis, pulmonary fibrosis/infiltrate,<span style=""text-align: center;"">&nbsp;SLE-like syndrome</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> <span style=""color: rgb(0, 255, 0);"">Bundle branch block,&nbsp;cholestatic jaundice, Clostridium difficile–associated diarrhea, hepatitis, anemia, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, angioedema, exfoliative dermatitis, Stevens-Johnson syndrome, superinfection</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <div style=""text-align: left;""><i>Active UTI</i></div><div><ul><li>Adult/Child &gt;12 yr: PO 50-100 mg qid after meals for 7 days or at least 3 days after the urine is sterile</li></ul><i>UTI Prevention</i><br><ul><li>Adult: PO 50-100 mg qPM</li></ul></div></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul style=""color: rgb(0, 255, 0);""><li>Urinary tract infection: Assess for burning, pain on urination, fever; cloudy, foul-smelling urine; I&amp;O ratio; C&amp;S before treatment, after completion; serum creatinine, BUN</li><li>Monitor blood count during chronic therapy (CBC, LFTs)</li><li>Assess allergy: Fever, flushing, rash, urticaria, pruritus</li><li>Hepatotoxicity: Assess for yellowing of skin, eyes, dark urine, clay-colored stools; monitor AST, ALT, stop drug immediately in hepatitis</li><li>Pulmonary fibrosis, pneumonitis: Assess for dyspnea, tachypnea, persistent cough</li><li>Serious skin disorders: assess for fever, flushing, rash, urticaria, pruritus<br></li><li>Peripheral neuropathy: Assess for paresthesias (more common in diabetes mellitus, electrolyte imbalances, vit B deficiency, debilitated patients)</li><li>CDAD: Assess for diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC and low serum albumin; stop product and usually give either vancomycin or IV metroNIDAZOLE</li><li>Beers: Avoid in older adults, potential for pulmonary, hepatic toxicity, peripheral neuropathy</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><b><span style=""color: rgb(255, 0, 0);"">Penicillin G</span></b></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> Penicillin</span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <div style=""text-align: left;"">Respiratory tract infections, scarlet fever, erysipelas, otitis media, pneumonia, skin and soft tissue infections, gonorrhea<br></div></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> Interferes with cell wall replication of susceptible organisms; osmotically unstable cell wall swells and bursts from osmotic pressure, resulting in cell death</span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Lethargy, hallucinations, anxiety, depression, twitching, hyperreflexia, nausea, vomiting, diarrhea, increased AST, ALT, abdominal pain, glossitis, colitis, vaginitis, moniliasis, glomerulonephritis, renal tubular damage, anemia, increased bleeding time, hemolytic anemia, hyperkalemia, hypokalemia, alkalosis, hypernatremia, local pain, tenderness and fever with IM inj</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> Coma, seizures,&nbsp;CDAD oliguria, proteinuria, hematuria, glomerulonephritis,&nbsp;bone marrow depression, granulocytopenia, anaphylaxis serum sickness, Stevens-Johnson syndrome</span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <i>Early syphilis</i><br><ul><li>Adult: IM 2.4 million units in single dose</li></ul><i>Prophylaxis of rheumatic fever, glomerulonephritis</i><br><ul><li>Adult and child &gt;27 kg: IM 1.2 million units as a single dose</li></ul><i>Most infections</i><br><ul><li>Adult/child &gt;27 kg: IM 1.2 million units in single dose</li></ul><br></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul><li>Assess patient for previous sensitivity reaction to penicillins or cephalosporins; cross-sensitivity between penicillins and cephalosporins is common</li><li>Assess patient for signs and symptoms of infection including characteristics of wounds, sputum, urine, stool, WBC &gt;10,000/mm3, earache, fever; obtain information baseline, during treatment</li><li>Obtain C&amp;S before beginning drug therapy to identify if correct treatment has been initiated, may start treatment before results are received</li><li>Assess for allergic reactions: Rash, urticaria, pruritus, chills, fever, joint pain; angioedema may occur a few days after therapy begins; EPINEPHrine, resuscitation equipment should be available for anaphylactic reaction</li><li>CDAD: Assess for diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC and low serum albumin; stop product and usually give either vancomycin or IV metroNIDAZOLE</li><li>Identify urine output; if decreasing, notify prescriber (may indicate nephrotoxicity); also check for increased BUN, creatinine</li><li>Monitor blood studies: AST, ALT, CBC, Hct, bilirubin, LDH, alkaline phosphatase, Coombs’ test monthly if patient is on long-term therapy</li><li>Monitor electrolytes: Potassium, sodium, chloride monthly if patient is on long-term therapy</li><li>Assess bowel pattern daily; if severe diarrhea occurs, product should be discontinued; may indicate CDAD</li><li>Monitor for bleeding: Ecchymosis, bleeding gums, hematuria, stool guaiac daily if on long-term therapy</li><li>Assess for overgrowth of infection: Perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center""><font color=""#ff0000""><b>Vancomycin</b></font></span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> Tricyclic glycopeptide</span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> MRSA, MSSA, Group B Streptococci, endocarditis prophylaxis for dental procedures, bacteremia, joint/bone infections, osteomyelitis, pneumonia, septicemia</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> Inhibits bacterial cell wall synthesis, blocks glycopeptides</span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> Headache, hypotension, peripheral edema, ototoxicity, nausea, chills, fever, rash, thrombophlebitis at inj site, (red man syndrome), skin/subcutaneous tissue disorders, back pain</span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> CDAD,&nbsp;nephrotoxicity,&nbsp;leukopenia, eosinophilia, neutropenia, anaphylaxis, superinfection</span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <i>Serious systemic infections</i><br><ul><li>Adult: IV 500 mg (7.5 mg/kg) q6-8hr or 1 g (15 mg/kg) q12hr or 15-20 mg/kg q12hr 20 to 35 mg/kg/dose (max: 3,000 mg/dose) loading dose, followed by 15 to 20 mg/kg/dose q8-12hr; adjust dose based on target PK/PD parameter. Consider loading dose in critically ill patients</li></ul><i>CDAD</i><br><ul><li>Adult: PO 125 mg qid × 10-14 days</li></ul><i>Staphylococcal endocarditis</i><br><ul><li>Adult: IV 25 to 30 mg/kg (actual body weight) loading dose for seriously-ill patients, then 15 to 20 mg/kg/dose (actual body weight) q8-12hr per guidelines</li></ul><i>Staphylococcal enterocolitis</i><br><ul><li>Adult: PO 500-2000 mg/day in 3-4 divided doses × 7-10 days</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><ul><li>Assess for infection: WBC, urine, stools, sputum, wound characteristics, VS, baseline and throughout treatment, obtain C&amp;S before starting treatment, may start treatment before results are received</li><li>Nephrotoxicity: Monitor I&amp;O ratio, BUN, creatinine; report hematuria, oliguria because nephrotoxicity may occur</li><li>Monitor blood tests: WBC; serum levels; peak 1 hr after 1-hr INF 25-40 mg/L; trough before next dose 5-10 mg/L, especially in renal disease, no trough levels are needed for PO form</li><li>CDAD: Assess for watery or bloody diarrhea, abdominal cramps, fever, pus, mucus, nausea, dehydration, discontinue immediately</li><li>Assess auditory function during, after treatment; hearing loss, ringing, roaring in ears; product should be discontinued, this evaluates the 8th cranial nerve; those with mild renal impairment or geriatrics are at greater risk</li><li>Monitor B/P during IV administration; sudden drop may indicate red man syndrome</li><li>Red man syndrome: Assess for flushing of neck, face, upper body, arms, back; may lead to anaphylaxis, slow IV infusion to &gt;1 hr</li><li>Superinfection: Monitor for vaginal itching; black, hairy tongue; loose, foul-smelling stools</li><li>Anaphylaxis: Assess for rash, itching, wheezing, trouble breathing; keep emergency equipment nearby with EPINEPHrine; if anaphylaxis occurs discontinue immediately and provide emergency intervention</li><li>Labs: CBC, albumin in urine, decreased specific gravity, renal function studies</li></ul></span>"
"<span style=""color:red; font-weight:bold; text-allign:center"">Amoxicillin</span>"	"<span style=""color:lime; font-weight:bold; text-decoration:underline"">Class:</span><span style=""color:lime""> <span style=""text-align: center;"">Penicillin</span></span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Indication:</span><span style=""color:white""> <span style=""text-align: center;"">Infections of respiratory tract, skin, GI tract, GU tract, otitis media, meningitis, septicemia, sinusitis, anthrax treatment and prophylaxis, and bacterial endocarditis prophylaxis, ulcers due to Helicobacter pylori</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Mechanism of Action:</span><span style=""color:lime""> Interferes with cell wall replication of susceptible organisms by binding to the bacterial cell wall; the cell wall; bactericidal, lysis mediated by bacterial cell wall autolysis</span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Common Side Effects:</span><span style=""color:white""> <span style=""color: rgb(255, 255, 255);"">Headache, nausea, vomiting, diarrhea, increased AST, ALT, anemia. uticaria, rash, overgrowth of infection</span></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Adverse Effects:</span><span style=""color:lime""> Seizures, CDAD,&nbsp;bone marrow depression, granulocytopenia, hemolytic anemia, eosinophilia, thrombocytopenia, agranulocytosis, anaphylaxis, serum sickness</span>
<hr>
<span style=""color:white; font-weight:bold; text-decoration:underline"">Route(s) and Dose(s):</span><span style=""color:white""><br> <i>Most respiratory infections</i><br><ul><li>Adults: PO (immediate-release) 500 mg q12hr or 250 mg q8hr for mild/moderate infections and 875 mg q12hr or 500 mg q8hr for severe infections</li></ul><i>Tonsillitis and/or pharyngitis (rheumatic fever prophylaxis) secondary to Streptococcus pyogenes</i><br><ul><li>Adults, adolescents, and children 12 yr and older PO (Moxatag 775 mg ext rel tabs) 775 mg qday, given within 1 hr of completing a meal, for 10 days</li><li>Adults: PO (immediate-release) 1 g qday or 500 mg bid for 10 days</li></ul><i>Acute otitis media</i><br><ul><li>Adults: PO (immediate-release) 500 mg q12hr or 250 mg q8hr for mild/moderate infections and 875 mg q12hr or 500 mg q8hr for severe infections</li></ul><i>H. Pylori</i><br><ul><li>Adult PO 1000 mg bid with lansoprazole 30 mg bid with clarithromycin 500 mg bid × 14 days or 1000 mg bid with omeprazole 20 mg bid, with clarithromycin 500 mg bid × 14 days or 1000 mg bid with esomeprazole 40 mg daily with clarithromycin 500 mg bid × 10 day; 1000 mg tid with lansoprazole 30 mg tid × 14 days</li></ul><i>Gonorrhea</i><br><ul><li>Adult and child ≥ 40 kg: PO 3 g single dose Child PO &gt;2 yr and &lt;40 kg: 50 mg/kg with probenecid 25 mg/kg single dose</li></ul><i>Prevention of endocarditis</i><br><ul><li>Adult PO 2 g 60 min prior to procedure</li></ul></span>
<hr>
<span style=""color:lime; font-weight:bold; text-decoration:underline"">Nursing Considerations:</span><span style=""color:lime""><br><li>Assess patient for previous sensitivity reaction to penicillins or other cephalosporins; cross-sensitivity between penicillin products and cephalosporins is common</li><li>Assess patient for signs and symptoms of infection, including characteristics of wounds, sputum, urine, stool, WBC &gt;10,000/mm3, earache, fever; obtain baseline information and monitor symptoms during treatment</li><li>Obtain C&amp;S before beginning product therapy to identify if correct treatment has been initiated, may be started before results are received</li><li>Assess for allergic reactions during treatment: rash, urticaria, pruritus, chills, fever, joint pain; angioedema may occur a few days after therapy begins; EPINEPHrine and resuscitation equipment should be available for anaphylactic reactions, rash is more common if allopurinol is taken concurrently</li><li>CDAD: Assess bowel pattern daily; diarrhea, cramping, fever, blood in stools; if severe diarrhea occurs, notify prescriber; product should be discontinued; CDAD may occur even weeks after discontinuing product</li></span>"
